Your browser doesn't support javascript.
loading
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma.
Au, Lewis; Hatipoglu, Emine; Robert de Massy, Marc; Litchfield, Kevin; Beattie, Gordon; Rowan, Andrew; Schnidrig, Desiree; Thompson, Rachael; Byrne, Fiona; Horswell, Stuart; Fotiadis, Nicos; Hazell, Steve; Nicol, David; Shepherd, Scott T C; Fendler, Annika; Mason, Robert; Del Rosario, Lyra; Edmonds, Kim; Lingard, Karla; Sarker, Sarah; Mangwende, Mary; Carlyle, Eleanor; Attig, Jan; Joshi, Kroopa; Uddin, Imran; Becker, Pablo D; Sunderland, Mariana Werner; Akarca, Ayse; Puccio, Ignazio; Yang, William W; Lund, Tom; Dhillon, Kim; Vasquez, Marcos Duran; Ghorani, Ehsan; Xu, Hang; Spencer, Charlotte; López, José I; Green, Anna; Mahadeva, Ula; Borg, Elaine; Mitchison, Miriam; Moore, David A; Proctor, Ian; Falzon, Mary; Pickering, Lisa; Furness, Andrew J S; Reading, James L; Salgado, Roberto; Marafioti, Teresa; Jamal-Hanjani, Mariam.
Afiliação
  • Au L; Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Renal and Skin Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
  • Hatipoglu E; Renal and Skin Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK; Cancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London WC1E 6DD, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute
  • Robert de Massy M; Cancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London WC1E 6DD, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK.
  • Litchfield K; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
  • Beattie G; Cancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London WC1E 6DD, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK.
  • Rowan A; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
  • Schnidrig D; Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
  • Thompson R; Retroviral Immunology, The Francis Crick Institute, London NW1 1AT, UK.
  • Byrne F; Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
  • Horswell S; Department of Bioinformatics and Biostatistics, The Francis Crick Institute, London NW1 1AT, UK.
  • Fotiadis N; Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden Hospital, London SW3 6JJ, UK.
  • Hazell S; Department of Pathology, the Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
  • Nicol D; Department of Urology, the Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
  • Shepherd STC; Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Renal and Skin Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
  • Fendler A; Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
  • Mason R; Renal and Skin Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
  • Del Rosario L; Renal and Skin Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
  • Edmonds K; Renal and Skin Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
  • Lingard K; Renal and Skin Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
  • Sarker S; Renal and Skin Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
  • Mangwende M; Renal and Skin Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
  • Carlyle E; Renal and Skin Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
  • Attig J; Retroviral Immunology, The Francis Crick Institute, London NW1 1AT, UK.
  • Joshi K; Cancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London WC1E 6DD, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK.
  • Uddin I; Cancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London WC1E 6DD, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK; Division of Infection and Immunity, University College Lon
  • Becker PD; Cancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London WC1E 6DD, UK.
  • Sunderland MW; Cancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London WC1E 6DD, UK.
  • Akarca A; Department of Cellular Pathology, University College London Hospital, London NW1 2BU, UK.
  • Puccio I; Department of Cellular Pathology, University College London Hospital, London NW1 2BU, UK.
  • Yang WW; Department of Cellular Pathology, University College London Hospital, London NW1 2BU, UK.
  • Lund T; Translational Immune Oncology Lab, Centre for Molecular Pathology, The Royal Marsden Hospital, Sutton SM2 5PT, UK.
  • Dhillon K; Department of Cellular Pathology, University College London Hospital, London NW1 2BU, UK.
  • Vasquez MD; Cancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London WC1E 6DD, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK.
  • Ghorani E; Cancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London WC1E 6DD, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK.
  • Xu H; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
  • Spencer C; Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
  • López JI; Department of Pathology, Cruces University Hospital, Biocruces-Bizkaia Institute, 48903 Barakaldo, Bizkaia, Spain.
  • Green A; Department of Cellular Pathology, Guy's & St Thomas' NHS Foundation Trust, St Thomas' Hospital, London SE1 7EH, UK.
  • Mahadeva U; Department of Cellular Pathology, Guy's & St Thomas' NHS Foundation Trust, St Thomas' Hospital, London SE1 7EH, UK.
  • Borg E; Department of Cellular Pathology, University College London Hospital, London NW1 2BU, UK.
  • Mitchison M; Department of Cellular Pathology, University College London Hospital, London NW1 2BU, UK.
  • Moore DA; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK; Department of Cellular Pathology, University College London Hospital, London NW1 2BU, UK.
  • Proctor I; Department of Cellular Pathology, University College London Hospital, London NW1 2BU, UK.
  • Falzon M; Department of Cellular Pathology, University College London Hospital, London NW1 2BU, UK.
  • Pickering L; Renal and Skin Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
  • Furness AJS; Renal and Skin Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
  • Reading JL; Cancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London WC1E 6DD, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK.
  • Salgado R; Division of Research, Peter MacCallum Cancer Centre, Melbourne VIC 300, Australia; Department of Pathology, GZA-ZNA Hospitals, Wilrijk, Antwerp, Belgium.
  • Marafioti T; Department of Cellular Pathology, University College London Hospital, London NW1 2BU, UK.
  • Jamal-Hanjani M; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK; Cancer Metastasis Laboratory, University College London Cancer Institute, London WC1E 6DD, UK; Department of Medical Oncology, University College London Hospitals, London NW1 2BU, UK
Cancer Cell ; 39(11): 1497-1518.e11, 2021 11 08.
Article em En | MEDLINE | ID: mdl-34715028
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Receptores de Antígenos de Linfócitos T / Resistencia a Medicamentos Antineoplásicos / Nivolumabe / Inibidores de Checkpoint Imunológico / Neoplasias Renais Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Cancer Cell Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Receptores de Antígenos de Linfócitos T / Resistencia a Medicamentos Antineoplásicos / Nivolumabe / Inibidores de Checkpoint Imunológico / Neoplasias Renais Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Cancer Cell Ano de publicação: 2021 Tipo de documento: Article